Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$5.21
▼ $0.03 (-0.6%)
Market data updated: 09/18 10:04 AM
Fundamentals updated: 09/17/2026
News analyzed: 09/18/2026
Market Cap
$13.68M
Day Range
$5.04 - $5.38
52-Week Range
$1.31 - $10.75
Beta
—
Next Earnings
11.11.2026
ADIL is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-40.1% (1Y)
Strengths: 10/22 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 82.5%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 11.3% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
56
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
4d ago · $4.90
Evidence: Narrative Gap moved from 30 to -3 day-over-day
What happened after
Still awaiting outcome
4d ago · $4.90
Evidence: Panic-selling score jumped from 7 to 34 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
66
Quality
No data available
Value
55
Momentum
51
Risk
40
Sentiment
86
Fundamental
46
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Adial Pharmaceuticals has centered on its financial and strategic developments. The company announced a **$32 million financing tranche** and an **acquisition of Azora Therapeutics**, alongside leadership expansions. Investor interest surged following these moves, with **ADIL stock rallying**—noted as its best day in over five years—amid pipeline updates and capital-raising efforts. No major clinical or operational updates were highlighted beyond these transactions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Adial Pharmaceuticals, Inc. News trend score: 86. Reason: 6 of the last 13 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
41
🎯 Conviction (vs. Emotion)
50
Psychology
48
Fundamentals
46
Technical
51
Valuation
55
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+102%
Market Narrative
51
Fundamental Reality
50
Narrative Gap
+1
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ADIL’s market behavior suggests a dominant euphoric state, where extreme momentum (+23.6% ROC) and overperformance (+172.2% above 200-day average) align with overconfidence and anchoring. The narrative gap (30 points) hints at a disconnect between optimistic expectations and fundamentals, while FOMO-driven buying persists despite modest volume. Key uncertainty lies in whether traders will sustain momentum or pivot as resistance nears. The low panic score contrasts with volatility (1.35x ATR), indicating traders remain bullish despite elevated risk.
Updated: 09/06/2026, 05:30 PM
What could change this?
👥 What the crowd believes
"$32 million tranche of financing closed (article 4) / up to $64 million financing (article 11)"
"acquires Azora Therapeutics (article 10, 11)"
"expands executive leadership team (article 5)"
🧠 Market Brain events driving this
📈 7D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect deep methodological contrasts. Benjamin Graham’s *Defensive* and *Enterprising* models both see strong value—Graham’s 100% score suggests a deep statistical discount, while his enterprising variant (85%) still flags it as a high-conviction opportunity. In contrast, Peter Lynch’s 100% score is a technicality: his model lacks growth data, so it can’t rule the stock out, but it doesn’t endorse it either. Meanwhile, Walter Bagehot’s 100% liquidity score implies resilience in a crisis, while Jesse Livermore’s 83% aligns with bullish price trends—both signaling stability and momentum. On the other end, the cautionary voices—Howard Marks (24%), Gerald Loeb (39%), and Samuel Nelson (0%)—highlight valuation risks, late-cycle concerns, or overbought conditions, while Charles Mackay’s 10% and Morgan Housel’s 0% suggest speculative crowd behavior or volatility that could unsettle patient investors. The divide underscores whether the stock’s fundamentals (or perceived safety) justify its risks or if it’s a speculative bet with hidden pitfalls.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 100
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 94
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 84
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 53
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 47
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 43
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 40
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 39
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 26
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 21
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (5 bullish · 7 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-151.2%
ROA
-119.5%
ROIC
—
EPS
-$11.93
Cash
$5.88M
Total Debt
—
Current Ratio
4.42
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$7.89
Tangible Book Value per Share (Tangible NAV)
$7.89
Sentiment based on basic keywords (not AI) — 6 positive, 7 neutral, 0 negative out of the last 13 articles.
Benzinga · 11.9.2026
Benzinga · 28.8.2026
GlobeNewswire · 25.8.2026
GlobeNewswire · 17.8.2026
Benzinga · 24.7.2026
MT Newswires · 16.6.2026
GlobeNewswire · 16.6.2026
MT Newswires · 11.6.2026
MT Newswires · 11.6.2026
MT Newswires · 11.6.2026
Stocktwits · 11.6.2026
MT Newswires · 11.6.2026
GlobeNewswire · 11.6.2026
Adial Pharmaceuticals, Inc (ADIL) currently has a StockIQ AI score of 56/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ADIL currently scores 56/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ADIL's technical score is 51/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 82.5%; Net income growth: 39.6%; Current ratio: 4.42.
Based on the real signals StockIQ computed: ATR: 11.3% of price; Calmar: -0.59 (3y annualized return -57.9% / max drawdown 98.3%); Return on equity (ROE): -151.2% (negative).
StockIQ has no recorded dividend payment history for ADIL.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 12 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Coastlands Capital LP | Open Market Purchase | 16.7.2026 | 1,233 | +1,233 | $2.75 |
| Coastlands Capital LP | Open Market Purchase | 16.7.2026 | 388,308 | +1,233 | $2.75 |
| Coastlands Capital LP | Open Market Purchase | 14.7.2026 | 2,000 | +2,000 | $2.65 |
| Coastlands Capital LP | Open Market Purchase | 14.7.2026 | 387,075 | +2,000 | $2.65 |
| Coastlands Capital LP | Open Market Purchase | 10.7.2026 | 1,700 | +1,700 | $2.70 |
| Coastlands Capital LP | Open Market Purchase | 10.7.2026 | 385,075 | +1,700 | $2.70 |
| Coastlands Capital LP | Open Market Purchase | 9.7.2026 | 10,053 | +10,053 | $2.79 |
| Coastlands Capital LP | Open Market Purchase | 9.7.2026 | 383,375 | +10,053 | $2.79 |
| Coastlands Capital LP | Open Market Purchase | 29.6.2026 | 25,000 | +25,000 | $2.60 |
| Coastlands Capital LP | Open Market Purchase | 29.6.2026 | 373,322 | +25,000 | $2.60 |
| Young Wendy B. | Open Market Purchase | 12.6.2026 | 36,378 | +36,378 | $2.75 |
| Davidson Matt | Grant/Award from Employer | 12.6.2026 | 232,417 | +232,417 | — |
| Davidson Matt | Grant/Award from Employer | 12.6.2026 | 232,417 | +232,417 | — |
| Young Wendy B. | Open Market Purchase | 12.6.2026 | 36,378 | +36,378 | $2.75 |
| Davidson Matt | Grant/Award from Employer | 12.6.2026 | 297,491 | +232,417 | — |
| Davidson Matt | Grant/Award from Employer | 12.6.2026 | 232,417 | +232,417 | — |
| Davidson Matt | Grant/Award from Employer | 11.6.2026 | 101.298 | +101.298 | — |
| Davidson Matt | Grant/Award from Employer | 11.6.2026 | 61,647 | +61,647 | — |
| Davidson Matt | Grant/Award from Employer | 11.6.2026 | 1,822.13 | +1,822.13 | — |
| Davidson Matt | Grant/Award from Employer | 11.6.2026 | 3,427 | +3,427 | — |
| Davidson Matt | Grant/Award from Employer | 11.6.2026 | 61,647 | +61,647 | — |
| Davidson Matt | Grant/Award from Employer | 11.6.2026 | 3,427 | +3,427 | — |
| Davidson Matt | Grant/Award from Employer | 11.6.2026 | 1,822 | +1,822 | — |
| Davidson Matt | Grant/Award from Employer | 11.6.2026 | 1,923 | +101 | — |
| Goodman Tony | Grant/Award from Employer | 7.4.2026 | 26,510 | +26,510 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
244,723 shares short as of 2026-08-31 · vs. 233,654 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
37.3% of trading volume this week was short selling, vs. 40.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology